Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAIN-BCG: Gemcitabine Alternating With Intravesical BCG vs BCG Alone in Recurrent NMIBC
NCT07000084Phase 3Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine in non-muscle-invasive bladder cancer (NMIBC), sponsored by Cancer and Leukemia Group B. Started Jul 2025; status: recruiting.
02
Drugs
gemcitabine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07000084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000084.